AstraZeneca: licence deal with Theragnostics
(CercleFinance.com) - Theragnostics, an Anglo-US clinical-stage pharmaceutical firm, said that it had signed a licence agreement with AstraZeneca to develop new treatment options for cancer patients.
The company - which develops molecular radiotherapy for imaging and treating cancers - said the deal will strengthen its intellectual property (IP) in the field of PARP inhibitors.
PARP inhibitors are a novel class of oncology drugs that block an enzyme that cancer cells use in response to DNA damage, both endogenous and as caused by treatments such as chemotherapy.
Analysts estimate that sales for the PARPi class could peak at 4.8 billion dollars pear year by 2023.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The company - which develops molecular radiotherapy for imaging and treating cancers - said the deal will strengthen its intellectual property (IP) in the field of PARP inhibitors.
PARP inhibitors are a novel class of oncology drugs that block an enzyme that cancer cells use in response to DNA damage, both endogenous and as caused by treatments such as chemotherapy.
Analysts estimate that sales for the PARPi class could peak at 4.8 billion dollars pear year by 2023.
Copyright (c) 2019 CercleFinance.com. All rights reserved.